Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas Dec 3, 2018 09:15PM
New Data Added to TRINTELLIX® (vortioxetine) Labeling Demonstrated Superiority Over Escitalopram in Improving SSRI-Induced Sexual Dysfunction in Patients with Major Depressive Disorder Oct 22, 2018 08:55AM
Seattle Genetics (SGEN), Takeda Pharmaceutical Report Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS (Brentuximab Vedotin) Oct 1, 2018 06:48AM
Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma Oct 1, 2018 06:45AM
TRINTELLIX® (vortioxetine) Prescribing Information Now Includes New Data Showing Improvement in Processing Speed, an Important Aspect of Cognitive Function in Acute Major Depressive Disorder (MDD) May 2, 2018 05:36PM


Dec 10, 2017 08:00AM Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
Dec 10, 2017 08:00AM Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
Nov 8, 2017 09:00AM Takeda Recognizes ALK+ Day with Launch of tALK+ Initiative During November’s Lung Cancer Awareness Month
Nov 7, 2017 07:00AM Takeda and Portal Instruments Announce Collaboration to Develop Needle-Free Drug Delivery Device
Nov 6, 2017 10:00AM Takeda, Lundbeck and Advocate Health Care Research Study Aims to Enhance Patient-Provider Engagement in Major Depressive Disorder Treatment using Digital Technology
Oct 30, 2017 08:00AM Takeda and the New York Academy of Sciences Announce Innovators in Science Award Honorees
Sep 26, 2017 09:00AM Takeda Named To 2017 Working Mother "100 Best Companies" For Leadership In Family Benefits And Paid Leave
Jan 30, 2017 06:00PM Exelixis and Takeda Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan
Nov 10, 2016 08:00AM Takeda and the New York Academy of Sciences to Honor Commitment to Innovation in Key Areas of Therapeutic Focus
Jun 1, 2016 10:00AM Trintellix (vortioxetine) Now Available in U.S. Pharmacies
May 16, 2016 04:01PM Takeda and Lundbeck Present Vortioxetine Data at the American Psychiatric Association (APA) 2016 Annual Meeting
May 2, 2016 03:32PM Brintellix (vortioxetine) Renamed Trintellix (vortioxetine) in U.S. to Avoid Name Confusion
Mar 28, 2016 08:02PM Takeda and Lundbeck Receive Complete Response Letter for Brintellix® (vortioxetine) sNDA
Feb 3, 2016 08:36PM FDA Psychopharmacologic Drug Advisory Committee Supports the Effectiveness of Brintellix® (vortioxetine) in Treating Certain Aspects of Cognitive Dysfunction in Major Depressive Disorder (MDD)
Aug 10, 2015 06:36PM FDA Accepts a Supplemental New Drug Application for Review of Brintellix® (vortioxetine) Clinical Trial Data That Assessed Cognitive Function in Patients with Major Depressive Disorder
Mar 14, 2014 05:29PM Sucampo and Takeda Announce Update on Liquid Formulation Program for AMITIZA(R) (lubiprostone)